A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Jonathan Welte
Advertisement
With Simon-Kucher & Partners’ life sciences division
Articles by Jonathan Welte
Advertisement
Latest Updated Articles
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentPublished: June 20th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
How Will the Inclusion of GLP-1s in Medicaid and Medicare Impact Businesses?
2
How are New FDA Programs Impacting Neuroscience?
3
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
4
Will the Industry Continue to Research Psychedelics?
5
